Abstract
Cancer has been the first cause of death in Japan since 1981. As for solid cancers, local therapies as surgical operation have been and still are the main means to cure them. However, for half of the cancer patients who will develop or already have metastatic diseases, systemic therapy is needed to control the disease and to maintain good quality of their life. Recently, standard regimens, i. e. evidence based scheduled anti-cancer drug administration, are used in most facilities, assuring the quality of the treatment. On the other hand, recent development of anti-cancer agents including molecular target drugs increases complexities of the treatments. To manage anti-cancer drug therapies, we described a generic clinical process chart. It involves an adaptation of the regimen, monitoring of adverse effects, evaluation of clinical benefits, and logic that switch the process. By using it, we can not only ensure the safety of the therapies, but analyze the quality of them. Additionally, multidisciplinary cancer treatment board to discuss about difficult cases is to be organized in facilities that provide cancer care.
